Within the vast surfaceome heterogeneity, we identify CD44 as a common and abundantly expressed surface antigen with high endocytic capacity to deliver ADC drugs that should stimulate intensified efforts in the development of CD44-targeteted ADCs in GBM treatment. This evidence concerns the gene CD44 and glioblastoma.